Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
101M
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
78.6M
-
Shares change
-
+17.4M
-
Total reported value, excl. options
-
$938M
-
Value change
-
+$206M
-
Put/Call ratio
-
0.77
-
Number of buys
-
98
-
Number of sells
-
-47
-
Price
-
$11.94
Significant Holders of Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (DAWN) as of Q2 2023
167 filings reported holding DAWN - Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (DAWN) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78.6M shares
of 101M outstanding shares and own 77.59% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (7.81M shares), Atlas Venture Life Science Advisors, LLC (7.61M shares), FMR LLC (7.56M shares), VANGUARD GROUP INC (4.28M shares), FRANKLIN RESOURCES INC (4.07M shares), BlackRock Inc. (3.56M shares), BRAIDWELL LP (3.36M shares), STATE STREET CORP (3.35M shares), VIKING GLOBAL INVESTORS LP (2.56M shares), and Canaan Partners XI LLC (2.55M shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.